Vivani Medical (VANI) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
The annual meeting will be held virtually on June 24, 2026, with shareholders able to vote online, by phone, mail, or during the webcast.
Four main proposals are up for vote: election of six directors, advisory approval of executive compensation, approval of the amended 2022 Omnibus Incentive Plan, and ratification of BPM LLP as auditor.
The board recommends voting in favor of all proposals and emphasizes the importance of shareholder participation.
Voting matters and shareholder proposals
Shareholders will vote on electing six directors, approving executive compensation, amending the 2022 Omnibus Incentive Plan, and ratifying BPM LLP as auditor.
The board recommends voting FOR all proposals.
Shareholders can submit proposals for the 2027 meeting by December 30, 2026, and must follow specific procedures for director nominations.
Board of directors and corporate governance
The board consists of six members, with one female director and a focus on diverse backgrounds and skills.
All directors except the CEO and his father are independent under Nasdaq rules.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, all meeting independence standards.
The board has adopted policies on insider trading, director diversity, and compensation recovery.
Latest events from Vivani Medical
- Q2 net loss narrowed to $6.4M, cash runway through Q2 2027, SLIM-1 trial and spin-off progress.VANI
Q2 2026 - Novo Nordisk will evaluate a GLP-1 implant as clinical trials launch in August, targeting obesity care.VANI
Emerging Growth Conference - Ultra long-acting GLP-1 implant shows promise for obesity with strong clinical and strategic momentum.VANI
Corporate presentation - Ultra long-acting GLP-1 implant targets obesity with durable results and strong adoption outlook.VANI
Corporate presentation - GLP-1 implant offers infrequent dosing and improved adherence for obesity management.VANI
Jefferies Global Healthcare Conference 2026 - Q1 2026 net loss was $6.8M; cash runway through H1 2027 depends on new funding and spin-off plans.VANI
Q1 2026 - Virtual meeting to elect directors, approve pay, incentive plan, and auditor for 2026.VANI
Proxy filing - Long-acting GLP-1 implants promise improved adherence and outcomes in obesity care.VANI
Corporate presentation - Advanced semaglutide implant program and secured funding to support operations into mid-2027.VANI
Q4 2025